Proteomics technologies permit the simultaneous analysis of multiple targets, and have become very powerful tools in rheumatology research. In osteoarthritis (OA), accurate diagnosis at early stages and monitoring of therapeutic strategies are essential unmet needs that are being faced with proteomic strategies. In these two areas, the discovery and application of novel, non-invasive, specific biochemical markers remains to be achieved. Furthermore, ongoing research is also attempting to increase the knowledge on the complex OA pathogenesis, in order to identify novel therapeutic targets and effective drugs. According to this, proteomic analyses focused on the study of those mechanisms that play a role in OA onset and progression have led to the identification of several proteins that were not previously related with the disease.
Altogether, proteomics has demonstrated in the recent years a big power for the discovery of newer protein candidates useful for early diagnosis and drug development or monitoring in OA. Considering that this disease involves several tissues and complex biological processes, combining existing biomarkers with novel protein candidates and even genetic markers appears to be a promising strategy to improve their accuracy. Nevertheless, still great efforts need to be made to impel the development of robust clinical assays that would allow the qualification and validation of those novel biomarkers that are being described by these large-scale analytical strategies before they can be employed in clinical routines.
Disclosure of Interest None Declared